Phenomenome Discoveries Inc. (PDI) is a human health research company that uses its patented metabolomic biomarker discovery platform and patented informatic research tools to discover novel metabolite biomarkers. PDI has small molecule serum biomarker discovery programs in cancer and neurodegenerative disease, and has validated and filed patents on diagnostic biomarkers in multiple human health disorders.
In 2012, PDI launched COLOGIC, together with its Canadian market commercialization partner, CML HealthCare Inc. COLOGIC is a simple blood test that screens for colorectal cancer. This is the first step in the global commercialization strategy for this test, and others like it in PDI's research and development pipeline.
PDI is uniquely positioned within the market, offering expertise in discovery and subsequent elucidation of the biological relevance of biomarkers as well as the development of highly efficient targeted assays for validated, relevant biomarkers. PDI is located in Saskatoon, Canada, and was founded in 2000.